ClinicalTrials.gg
WithdrawnNCT06394206BIPEHUpdated Oct 28, 2026

Benefit of a Hospital Intervention in Patients With Hepatic Steatosis

An interventional study of Specialized Unit and Usual Follow-Up in Hepatic Steatosis, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Withdrawn at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Not applicable, Interventional, and Supportive care

How we know

Why this study was withdrawn
Funding issues
Updated Oct 28, 2026Now WithdrawnEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.

Enrollment
23rd of 23
0 · median 165
Started
2025
with 2 others
No phase
12 of 28
1 open now
Registered
19th of 28
by date
Lead sponsor
2 of 28
Consorci Sanitari de l'Alt Penedès i Garraf

Among the 28 studies in Fatty Liver with a site in Spain, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 with no phase, and was the 19th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Fatty Liver with a site in Spain, or all of them as a file.
02

Study summary

The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults. The primary questions it aims to answer are:

  • Does this specialized consultation increase the number of patients with hepatic steatosis who show improvement after one year of clinical follow-up in said consultation?

The improvement of the disease will be assessed through the following parameters:

  • liver laboratory tests
  • weight loss
  • improvement in cholesterol and triglyceride levels. Researchers will compare follow-up in the specialized consultation to standard follow-up to assess the effectiveness of the specialized consultation in treating hepatic steatosis.

Participants will be randomly assigned to two groups. The first group will be visited in the specialized consultation every three months for one year and will continue to receive the rest of their follow-up visits. The second group will undergo their usual follow-up visits but will not be visited in the specialized consultation.

03

Conditions studied

  • Hepatic Steatosis

Keywords

  • Fatty Liver
  • Metabolic Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients seen in outpatient gastroenterology clinics with hepatic steatosis.
  • Diagnosed with hepatic steatosis through ultrasound or abdominal CT scan
  • Mild to moderate fibrosis as assessed by elastography or FibroScan (F1-F3) or with a Fibrosis-4 (FIB-4) Index less than 3.5.
  • Signature of for study inclusion, either by the participant themselves or by their legal representative.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not have any hepatic imaging test conducted in the last 5 years.
  • Conditions other than hepatic steatosis requiring gastroenterological follow-up.
  • Abusive alcohol consumption, defined as weekly intake of > 50 g in women and more than 70 g in men.
  • Cognitive or affective disorders limiting the ability to cooperate with study procedures.
  • Participation in another clinical trial involving experimental intervention during the period of this trial and/or establishing visit schedules incompatible with this trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Specialized Unit

    This group of participants will be visited in the specialized consultation and will continue to receive the rest of their follow-up visits.

    Other: Specialized Unit · Other: Usual Follow-Up

  • Active comparator
    Usual Follow-Up

    This group of participants will undergo their usual follow-up visits but will not be visited in the specialized consultation.

    Other: Usual Follow-Up

Interventions

  • OtherSpecialized Unit

    The participant will be visited every three months for one year

  • OtherUsual Follow-Up

    The participant will be visited as usual, it means they will be visited at Digestive Consultation

06

What researchers measure

Primary outcomes

  1. Discharge criteria from the gastroenterology clinic

    Percentage of patients meeting discharge criteria (defined by the trial) from the gastroenterology clinic at the end of the study

    Time frame: 1 year

Secondary outcomes

  1. Discharge from the gastroenterology clinic after achieving metabolic control goals

    Difference in the percentage of patients discharged from the gastroenterology clinic after achieving metabolic control goals

    Time frame: 1 year

  2. Change on Test de Owliver

    Change in the Owliver test compared to baseline

    Time frame: 1 year

  3. Change on liver enzymes

    Change compared to baseline in the liver enzymes (UI/mL)

    Time frame: 1 year

  4. Change on total cholesterol

    Change compared to baseline in the total cholesterol (mg/dL)

    Time frame: 1 year

  5. Change on LDL- cholesterol

    Change compared to baseline in the LDL- cholesterol (mg/dL)

    Time frame: 1 year

  6. Change on HDL- cholesterol

    Change compared to baseline in the HDL- cholesterol (mg/dL)

    Time frame: 1 year

  7. Change on triglycerides

    Change compared to baseline in the triglycerides (mg/dL)

    Time frame: 1 year

  8. Change on Fibrosis-4 Index

    Change compared to baseline on Fibrosis-4 Index

    Time frame: 1 year

  9. Change on Hepatic Fibrosis

    Change compared to baseline on Fibroscan score

    Time frame: 1 year

  10. Glycated hemoglobin

    In diabetic patients, change compared to baseline on glycated hemoglobin

    Time frame: 1 yera

  11. Insulin resistance

    In patients with insulin resistance, change compared to baseline on Insulin Resistance Index

    Time frame: 1 year

  12. Body Mass Index

    Change compared to baseline on body mass index

    Time frame: 1 year

07

Study locations

1 site
  • Consorci Sanitari Alt Penedes i Garraf
    Sant Pere de Ribes, Barcelona 08810, Spain
08

References and documents

Individual participant data

Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

Supporting information: Study protocol, Informed consent form

Time frame: After publication of main results of the study.

Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
May 1, 2024
StartEst.
Dec 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Funding issues
changed Oct 28, 2026
Sites
1 site added, 1 site removed
Show site
  • Consorci Sanitari Alt Penedes i Garraf · Sant Pere de Ribes, Spain
Show 1 removed
  • Consorci Sanitari Alt Penedes i Garraf · Sant Pere De Ribes, Spain
Oct 28, 2026
Enrollment
86 (estimated)→0 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Withdrawn
    Why stopped Funding issues
    1 site added, 1 site removed
    Show site
    • Consorci Sanitari Alt Penedes i Garraf · Sant Pere de Ribes, Spain
    Show 1 removed
    • Consorci Sanitari Alt Penedes i Garraf · Sant Pere De Ribes, Spain
    Enrollment 86 (estimated)→0 (actual)
    + 5 other changes: identifiers, verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06394206
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Dec 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Lidia Tikhomirova, MD
principal investigator · CSAPG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion